Loraxone

powder for solution for injection in vials No. 12

Instructions Normative documents

Composition

1 vial contains ceftriaxone sodium in terms of ceftriaxone – 500 or 1000 mg.

icon

Dosage form

Powder for solution for injection

icon

Pharmacological group

Antibacterial medications for systemic use. Cephalosporins of III generation. ATC code J01D D04

icon

Pharmacological properties

Ceftriaxone inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.

Commonly susceptible species

Gram-positive aerobes

Staphylococcus aureus (methicillin-susceptible)£

Staphylococci coagulase-negative (methicillin-susceptible)£

Streptococcus pyogenes (Group A)

Streptococcus agalactiae (Group B)

Streptococcus pneumoniae

Viridans Group Streptococci

Gram-negative aerobes

Borrelia burgdorferi

Haemophilus influenzae

Haemophilus parainfluenzae

Moraxella catarrhalis

Neisseria gonorrhoea

Neisseria meningitidis

Proteus mirabilis

Providencia spp

Treponema pallidum

icon

Indications

Ceftriaxone is indicated in the treatment of the following infections in adults and children including term neonates (from birth):

Bacterial Meningitis

Community acquired pneumonia

Hospital acquired pneumonia

Acute otitis media

Intra-abdominal infections

Complicated urinary tract infections (including pyelonephritis)

Infections of bones and joints

Complicated skin and soft tissue infections

Gonorrhoea

Syphilis

Bacterial endocarditis

Ceftriaxone may be used:

For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults

For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III)) in adults and children including neonates from 15 days of age.

For Pre-operative prophylaxis of surgical site infections

In the management of neutropenic patients with fever that is suspected to be due to a bacterial infection

In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above

icon

SIDE EFFECTS

The most frequently reported adverse reactions for ceftriaxone are eosinophilia, leucopenia, thrombocytopenia, diarrhoea, rash, and hepatic enzymes increased.

Attention!

The information provided in this section is intended only for medical and pharmaceutical professionals and can be used  in professional activity.

ARE YOU A HEALTH CARE SPECIALIST?

(When choosing the answer, you are responsible for the reliability of the information provided)

×